Hepcidin and Iron in Global Health (HIGH)

Conditions

Anaemia Haematological Disorders Iron deficiency anaemia

Wegmüller R, Bah A, Kendall L, Goheen MM, Sanyang S, Danso E, Sise EA, Jallow A, Verhoef H, Jallow MW, Wathuo M, Armitage AE, Drakesmith H, Pasricha SR, Cross JH, Cerami C, Prentice AM.

2023-01-0111 citations

10.1016/s2214-109x(22)00449-1

Efficacy and safety of hepcidin-based screen-and-treat approaches using two different doses versus a standard universal approach of iron supplementation in young children in rural Gambia: a double-blind randomised controlled trial

Rita Wegmüller, Amat Bah

UNC Libraries2019-08-18

10.17615/secn-5t79

Anemia Offers Stronger Protection Than Sickle Cell Trait Against the Erythrocytic Stage of Falciparum Malaria and This Protection Is Reversed by Iron Supplementation.

Goheen MM, Wegmüller R, Bah A, Darboe B, Danso E, Affara M, Gardner D, Patel JC, Prentice AM, Cerami C.

2016-11-0949 citations

10.1016/j.ebiom.2016.11.011

Efficacy and safety of hepcidin-based screen-and-treat approaches using two different doses versus a standard universal approach of iron supplementation in young children in rural Gambia: a double-blind randomised controlled trial.

Wegmüller R, Bah A, Kendall L, Goheen MM, Mulwa S, Cerami C, Moretti D, Prentice AM.

2016-09-0117 citations

10.1186/s12887-016-0689-4

Interventions

The participants will be randomly assigned (1:1:1 ratio) to either receive: 1. MNP containing 12 mg/day iron 2. MNP containing 12 mg/day iron or 0 mg/day iron based on

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Apparently healthy 2. Age: 6 to 23 months 3. Not severely malnourished (HAZ, WAZ >-3 SD and WHZ > -2 SD) 4. Hb = 7 g/dL and < 11 g/dL 5. Free of malaria 6. Resident in the study area 7. Ability and willingness to comply with the study protocol (weekly study visits with finger prick blood sampling) 8. Informed consent given by parent or guardian

Exclusion criteria

Exclusion criteria: 1. Congenital disorders 2. Chronic disease 3. Regular medication 4. Currently participating in another study

Design outcomes

Primary

Measure	Time frame
Haemoglobin concentration at study day 84	—

Secondary

Measure	Time frame
1. Proportion of anaemia at study day 84 2. Proportion of iron deficiency at day 84 3. Proportion of iron deficiency anaemia at day 84 4. Iron dosage 5. Morbidity 6. Safety 7. Amount of iron absorbed over the supplementation period	—

Countries

Gambia

Outcome results

None listed